With $117M in fresh cash, Amunix paves path to the clinic for 'universal mask' prodrug on the hunt for HER2 tumors

Kyle Blankenship

Despite all the excitement over the possibility of T cell therapies to crack the code against solid tumors, early safety data have limited the burgeoning …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With $117M in fresh cash, Amunix paves path to the clinic for 'universal mask' prodrug on the hunt for HER2 tumors

Kyle Blankenship

Sign up to read this article for free.

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

A look at biotech's year of the megaround

FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

With $117M in fresh cash, Amu­nix paves path to the clin­ic for 'u­ni­ver­sal mask' pro­drug on the hunt for HER2 tu­mors

Kyle Blankenship

Sign up to read this article for free.

more like this

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

A look at biotech's year of the megaround

FDA ad­comm to re­view No­var­tis' Fab­hal­ta in ul­tra-rare kid­ney dis­ease

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

With $117M in fresh cash, Amunix paves path to the clinic for 'universal mask' prodrug on the hunt for HER2 tumors

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes